Supply of amoxycillin (as trihydrate) (AMOXIL) 500 mg capsule blister pack by Aspen Pharmacare Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Commonwealth Parliament to regulate the supply of therapeutic goods in Australia, ensuring they are safe, of high quality, and that their benefits outweigh any risks. This legislation was introduced to address the need for a unified regulatory framework that governs the manufacturing, supply, and advertising of therapeutic goods, including medicines, medical devices, and blood products. The Act aims to protect public health by controlling the quality and safety of therapeutic goods available in the market. One of the key policy objectives of the Act is to facilitate timely access to therapeutic goods while maintaining rigorous standards to safeguard consumers. The Therapeutic Goods Administration, under the Department of Health, is responsible for administering this Act, ensuring compliance and overseeing the regulation of therapeutic goods. On November 28, 2013, the delegate of the Secretary of the Department of Health issued a consent under subsections 14 and 14A of the Therapeutic Goods Act 1989, allowing Aspen Pharmacare Australia Pty Ltd to supply a specific batch of amoxycillin 500 mg capsule blister packs that did not conform to certain labelling requirements as stipulated in Therapeutic Goods Order (TGO) 69. The consent was granted subject to conditions that ensure the correct information is disseminated to healthcare professionals and consumers to avoid any potential misunderstanding regarding the product's composition. This action underscores the Act's role in balancing regulatory compliance with the need to facilitate access to essential medicines while ensuring patient safety.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the supply, importation, or manufacture of therapeutic goods in Australia. This includes pharmaceutical products, medical devices, and related goods. The Act extends to the entire Commonwealth, ensuring a uniform standard for therapeutic goods across all states and territories. The Act governs various aspects of therapeutic goods, such as their quality, safety, and efficacy, as well as the conduct of those involved in their supply. In the context of the consent given to Aspen Pharmacare Australia Pty Ltd, the Act allows for specific exceptions and conditions to be imposed on the supply of goods that do not fully conform to prescribed standards. For instance, the consent granted to the company to supply a particular batch of amoxycillin capsules is contingent upon specific conditions being met, such as the provision of corrected information to healthcare providers and patients. These conditions are intended to mitigate any potential risks associated with the non-conformance of the product. The Act also provides for subordinate legislation and regulations, which can further extend or restrict the application of the primary Act, ensuring detailed and specific oversight of therapeutic goods within Australia.

Key Provisions

The Therapeutic Goods Act 1989, as referenced in the Gazette (C2013G01824), provides specific consent for the supply of a particular batch of amoxycillin (as trihydrate) 500 mg capsules (section 14). This consent is given by the delegate of the Secretary of the Department of Health, and it addresses a product that does not conform to certain specifications outlined in Therapeutic Goods Order (TGO) 69. Specifically, the product in question does not accurately express the quantity or proportion of the active ingredient, amoxycillin trihydrate, as required by paragraphs 3(2)(c) and 3(13)(a) of TGO 69. The consent granted under section 14(1) of the Act is specifically limited to batch 18427K833 of the foil labels of the starter pack, where the original labels incorrectly stated that the capsules contain 500 mg of amoxycillin trihydrate instead of amoxycillin. This consent comes with conditions aimed at ensuring that the product is supplied correctly and safely. The key condition is that the consent applies only to the specific batch of foil labels submitted with the company's application, which incorrectly labelled the capsules as containing 500 mg of amoxycillin trihydrate instead of amoxycillin. Additionally, a Dear Doctor letter dated November 25, 2013, must accompany the affected batch. This letter provides detailed information about the consent to supply, explaining the circumstances surrounding this exception and reminding patients to keep the blister foils with the correctly labelled cartons. The obligations imposed by this consent are primarily on Aspen Pharmacare Australia Pty Ltd, the entity responsible for supplying the product. The company must ensure that the batch in question is supplied with the correct information as outlined in the consent and conditions. This includes using the specific foil labels that were submitted with the application and providing the Dear Doctor letter to accompany the batch. Compliance with these conditions is crucial to ensure that the therapeutic product is supplied in a manner that does not mislead healthcare professionals or patients about the product's composition. Failure to comply with the conditions set out in the consent could result in significant legal and regulatory consequences. Under the Therapeutic Goods Act 1989, breaches of the conditions could lead to civil or criminal penalties. The maximum penalties for such breaches can include substantial fines and, in severe cases, imprisonment. The exact penalties would depend on the nature and extent of the breach, but they serve as a deterrent against non-compliance, ensuring that therapeutic products are supplied in accordance with the regulatory requirements designed to protect public health and safety.